

**Amendments to the Claims:**


This listing of claims will replace all prior versions and listing of claims in the application.

Please cancel claims 32 and 34-43 without prejudice or disclaimer. Please add new claims 44 to 49 as follows:


Claims 1-43. (canceled)

44. (new): A pharmaceutical formulation comprising:

a benzamide derivative represented by formula (1):



wherein A represents a structure shown by any one of formula (2):



or a pharmaceutically acceptable salt thereof;

an excipient selected from the group consisting of lactose, lactose anhydride, D-mannitol, corn starch, and crystalline cellulose;

a lubricant selected from the group consisting of magnesium stearate, calcium stearate, stearic acid, and talc;

a disintegrant selected from the group consisting of partly pregelatinized starch, carmellose calcium and carboxymethylstarch sodium; and

at least one member selected from the group consisting of an amino compound and an inorganic base,  
wherein

the amino compound is at least one member selected from the group consisting of tris(hydroxymethyl)aminomethane, monoethanolamine, diethanolamine, triethanolamine, diisopropanolamine, triisopropanolamine, dihydroxyaluminum aminoacetate, arginine, creatinine, sodium glutamate, glycine, L-arginine L-glutamate, and carbachol; and

the inorganic base is at least one member selected from the group consisting of sodium carbonate, potassium carbonate, ammonium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydroxide, disodium phosphate, and ammonia.

45. (new): The pharmaceutical formulation according to claim 44,  
wherein

the excipient is D-mannitol;


the lubricant is selected from the group consisting of magnesium stearate and talc;

the disintegrant is selected from the group consisting of partly pregelatinized starch, carmellose calcium and carboxymethylstarch sodium;


the amino compound is at least one member selected from the group consisting of tris(hydroxymethyl)aminomethane, monoethanolamine, diethanolamine, triethanolamine, diisopropanolamine, triisopropanolamine, dihydroxyaluminum aminoacetate, arginine, creatinine, sodium glutamate, glycine, L-arginine L-glutamate, and carbachol; and

the inorganic base is at least one member selected from the group consisting of sodium carbonate, potassium carbonate, ammonium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydroxide, disodium phosphate, and ammonia.

46. (new): A pharmaceutical formulation comprising:  
a benzamide derivative represented by formula (1):



wherein A represents a structure shown by any one of formula (2):



or a pharmaceutically acceptable salt thereof;

at least one solvent selected from the group consisting of propylene glycol, dimethylacetamide, and a polyethylene glycol; and

at least one member selected from the group consisting of an organic acid salt, an amino compound and an inorganic base;

wherein

the organic acid salt is at least one member selected from the group consisting of monosodium fumarate, sodium alginate, sodium dehydroacetate, sodium erythorbate, and trisodium citrate;

the amino compound is at least one member selected from the group consisting of tris(hydroxymethyl)aminomethane, monoethanolamine, diethanolamine, triethanolamine, diisopropanolamine, triisopropanolamine, dihydroxyaluminum aminoacetate, arginine, creatinine, sodium glutamate, glycine, L-arginine L-glutamate, and carbachol; and

the inorganic base is at least one member selected from the group consisting of sodium carbonate, potassium carbonate, ammonium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydroxide, disodium phosphate, and ammonia.

47. (new): The pharmaceutical formulation according to claim 46

wherein

the at least one solvent is polyethylene glycol 400; and  
the formulation is maintained at a pH in the range of about 7 to about 11 through addition of an acid or a base.

48. (new): The pharmaceutical formulation according to claim 47 wherein the acid is hydrochloric acid and the base is sodium hydroxide.

49. (new): The pharmaceutical formulation according to any one of claims 44 to 48, wherein the benzamide derivative is the compound of formula (3):

